Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 13Active not recruiting 4Completed 2Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 11Leukemia, Myeloid, Acute 10Glioblastoma 10Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Neoplasm Metastasis 7Colorectal Neoplasms 7Lung Neoplasms 6Carcinoma, Hepatocellular 6Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Pancreatic Neoplasms 5Myelodysplastic Syndromes 5Hematologic Neoplasms 5Ovarian Neoplasms 4Multiple Myeloma 4Glioma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Melanoma 3Head and Neck Neoplasms 3Astrocytoma 3Urinary Bladder Neoplasms 2Solid Tumors 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

iadademstat 1decitabine and cedazuridine drug combination 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Thrombocythemia, Essential × 90 days × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡